ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016 ACR/ARHP Annual Meeting
    • 2015 ACR/ARHP Annual Meeting
    • 2014 ACR/ARHP Annual Meeting
    • 2013 ACR/ARHP Annual Meeting
    • 2012 ACR/ARHP Annual Meeting
    • 2011 ACR/ARHP Annual Meeting
    • 2010 ACR/ARHP Annual Meeting
    • 2009 ACR/ARHP Annual Meeting
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "Adalimumab and spondylarthritis"

  • Abstract Number: 1560 • 2017 ACR/ARHP Annual Meeting

    Predictors of Long-Term Modified Minimal Disease Activity Response in Peripheral Spondyloarthritis Patients Treated with Adalimumab

    Laura C Coates1, Sonya Abraham2, William Tillett3, Philip J Mease4, Sofia Ramiro5, Tianshuang Wu6, Xin Wang6, Aileen L. Pangan6 and In-Ho Song6, 1University of Leeds and Leeds Teaching Hospitals NHS Trust, Leeds, Great Britain, 2NIHR/Wellcome CRF, Imperial College Healthcare NHS Trust, London, United Kingdom, 3Royal National Hospital for Rheumatic Diseases and University of Bath, Bath, United Kingdom, 4Swedish Medical Center and University of Washington, Seattle, WA, 5Rheumatology, Department of Rheumatology, LUMC, Leiden, Netherlands, Leiden, Netherlands, 6AbbVie Inc., North Chicago, IL

    Background/Purpose : There is a lack of validated outcome measures in non-psoriatic peripheral spondyloarthritis (pSpA). Therefore, a modified version of the minimal disease activity (mMDA)1…
  • Abstract Number: 1545 • 2014 ACR/ARHP Annual Meeting

    Better Performance of the Leeds and Sparcc Enthesitis Indices Compared to the Mases in Patients with Peripheral Spondyloarthritis during Treatment with Adalimumab

    Philip J. Mease1, Filip van Den Bosch2, Joachim Sieper3, Aileen L. Pangan4, Nupun A. Varothai4 and In-Ho Song5, 1Swedish Medical Center and University of Washington, Seattle, WA, 2Ghent University Hospital, Ghent, Belgium, 3Charité Universitätsmedizin Berlin, Berlin, Germany, 4AbbVie Inc., North Chicago, IL, 5AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany

    Background/Purpose: Peripheral spondyloarthritis (pSpA) is characterized by arthritis, enthesitis, and/or dactylitis. Enthesitis is considered a core outcome domain for SpA; however, there is no clear…
  • Abstract Number: 2439 • 2013 ACR/ARHP Annual Meeting

    Smoking Was Not Associated With Response To Adalimumab Therapy In Patients With Non-Radiographic Axial Spondyloarthritis

    Joachim Sieper1, Denis Poddubnyy2, Aileen L. Pangan3, Suchitrita S. Rathmann3 and Jaclyn K. Anderson3, 1Charité University Medicine Berlin, Berlin, Germany, 2Charité Universitätsmedizin Berlin, Berlin, Germany, 3AbbVie Inc., North Chicago, IL

    Background/Purpose: Cigarette smoking has been reported as a risk factor for early disease onset, higher disease activity, and poor function in patients (pts) with axial…
  • Abstract Number: 1801 • 2013 ACR/ARHP Annual Meeting

    Relationship Between MRI and Clinical Remission In Patients With Non-Radiographic Axial Spondyloarthritis After Two Years Of Adalimumab Therapy

    Désiréé van der Heijde1, Walter P. Maksymowych2, Joachim Sieper3, Robert Lambert4, Matthew A. Brown5, Suchitrita S. Rathmann6, Jaclyn K. Anderson6 and Aileen L. Pangan6, 1Leiden University Medical Center, Leiden, Netherlands, 2Medicine, University of Alberta, Edmonton, AB, Canada, 3Charité University Medicine Berlin, Berlin, Germany, 4Radiology, University of Alberta Hospital, Edmonton, AB, Canada, 5Translational Research Institute, University of Queensland Diamantina Institute, Brisbane, Australia, 6AbbVie Inc., North Chicago, IL

    Background/Purpose: Adalimumab (ADA) is currently approved in the EU for the treatment of severe non-radiographic axial spondyloarthritis (nr-axSpA), in patients (pts) with an elevated CRP…
  • Abstract Number: 1540 • 2013 ACR/ARHP Annual Meeting

    Sustained Clinical Remission In Patients With Non-Radiographic Axial Spondyloarthritis After Two Years Of Adalimumab Treatment

    Joachim Sieper1, Dominique L. Baeten2, Filip Van den Bosch3, Suchitrita S. Rathmann4, Jaclyn K. Anderson4 and Aileen L. Pangan4, 1Medical Department I, Rheumatology, Charité Universitätsmedizin Berlin, Campus Benjamin-Franklin, Berlin, Germany, 2Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, 3Ghent University Hospital, Ghent, Belgium, 4AbbVie Inc., North Chicago, IL

    Background/Purpose: Adalimumab (ADA) is currently approved in the EU for the treatment of severe non-radiographic axial spondyloarthritis (nr-axSpA), in patients (pts) with an elevated CRP…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Annual Meeting in Atlanta, Georgia

© COPYRIGHT 2019 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
This site uses cookies: Find out more.